CYTARINE (Cytarabine) is indicated primarily for induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. It has also been found to be useful in the treatment of other leukaemias such as acute lymphoblastic leukaemia or acute lymphocytic leukaemia, chronic myelocytic leukaemia (blastphase) and erythroleukaemia. CYTARINE (Cytarabine) may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy. Children with non-Hodgkin's lymphoma have benefited from a combination drug program (LSA2L2) that includes cytarabine. Remissions induced by CYTARINE (Cytarabine) not followed by maintenance treatment have been brief. Maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.
Sign Out
